Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Axsome is advancing an industry-leading neuroscience pipeline of multiple, innovative, late-stage, patent-protected product candidates addressing a broad range of serious psychiatric and ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by investment analysts at Truist Financial from $190.00 to $200.00 in a research note issued to investors on ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...